

CPSA - Where Technology and Solutions Meet

1998 Program Chairs

Mike S. Lee, Milestone Development Services Edward H. Kerns, Milestone Development Services

Plenary Lecture

Richard A. Yost, University of Florida

Pushing the Bioanalytical Envelope with Ion Trap Mass Spectrometry

Featured Symposia and Roundtables

Metabolism || Analysis Strategies || Emerging Technologies || Biomolecular Separations || Automation || Combinatorial Chemistry || Impurities, Degradants and Natural Products || Recruiting, Developing and Motivating Scientists || Outsourcing || Biomolecule Analysis || Pharmacokinetics

1999 Program Chair

Mike S. Lee, Milestone Development Services

Plenary Lecture

Richard M. Caprioli, Vanderbilt University

Mass Spectrometry Imaging: A Tool for the 21st Century

Featured Symposia and Roundtables

Proteomics || Sample Preparation || Combinatorial Chemistry || Automation || Fast Chromatography || Lead Optimization || Accelerated Drug Discovery || Using Dedicated Instruments || Well Characterized Biologics || Information Management || Lead Identification || Emerging Technologies

2000 Program Chair

Todd A. Gillespie, Eli Lilly and Company

Plenary Lecture

John R. Yates, The Scripps Research Institute

Proteomics Using Multidimensional Chromatography and Tandem Mass

Spectrometry

Featured Symposia and Roundtables

New Technologies and Approaches for Drug Metabolism || Sample Preparation || Chromatography || Structure and Purity Determination: How Much and When? || How to Demo/Purchase an LC/MS Instrument: Experiences and Perspectives || Drug Discovery in the Post-Genome Era: Proteomcs/Genomics || Predictive Models for Lead Optimization and Selection || Mass Spectrometry || Data Management || Mass Spectrometry in the QC Laboratory: Are We Ready? || Purification Systems for Combinatorial Chemistry || Is LC/TOF a Viable Bioanalytical Tool? || Data Management and Manipulation || Drugability High Throughput Screening || In Vitro Methods || New Technologies and Future Trends for High Throughput



Robyn A. Rourick, DuPont Pharmaceuticals

Plenary Lecture

Donald G. Robertson, Pfizer

Of Mice and Magnets: Metabonomic Technology as a Tool for Rapid-Throughput Toxicity Evaluation

Featured Symposia and Roundtables

Structure Profiling || Sample Preparation & Chromatography || High Throughput Synthesis Support: Open-Access Applications and Formats || The Emerging Future/Role of Proteomics in Drug Discovery || Pharmaceutical Property Profiling: Metrics and Implementation || Mass Spectrometry & Data Management || Hyphenated NMR Methods in Pharmaceutical R&D || Strategies for Overcoming the Bottlenecks in Assessing Toxicity || Predictive Models for Drug Discovery Screening || Technology Transfer: Drug Discovery to Drug Development Perspectives || Emerging Technologies

2002 Program Chair

Kenneth L. Morand, Procter & Gamble Pharmaceuticals

Plenary Lecture

Joseph A. DiMasi, Tufts Center for the Study of Drug Development Trends in the Economics of Pharmaceutical Innovation: Cost, Time, and Risk

Featured Symposia and Roundtables

Genomics/Post-Genomics Trends || Instrumentation for Protein Characterization: Emerging Trends in Proteomic Analysis || Metabonomics || Advances in Microfluidics Technology || The Value of the Corporate Compound Collection: Protecting Your Investment || Preclinical Lead Optimization: Are We Making A Difference? || Emerging Technologies for Drug Discovery & Development || Data Management in a High-Throughput Analysis Environment || Why Does Method Development Take So Long? || In-Source, Out-Source: What Do Pharmaceutical Companies Do for Bioanalytical Support? || Crystal City Guideline Review

2003 Program Chair

Nigel J. Clarke, ActivX Biosciences

Plenary Lecture

Simon J. Gaskell, The University of Manchester Institute of Science and Technology

The Multi-Dimensionality of the Proteome

Featured Symposia and Roundtables

Functional Proteomics: Quantitation || Discovery and Validation of Proteomic Biomarkers for Drug Development || Functional Proteomics: Relationships || Bioinformatics for Proteomics || Lead Optimization || Reactive Xenobiotic Intermediates || Compound Library Analysis and Profiling || Conversion of Data to Information: Dissemination of Information to Drive Therapeutic Area Projects || Recent Regulatory Guidance: Bioanalytical Impact on Drug Development || Bioanalytical LC/MS/MS Methods: Perspectives and Lessons Learned || Research Informatics in Drug Development



Steven A. Hofstadler, Ibis Therapeutics Mark Sanders, Bristol-Myers Squibb

Plenary Lecture

Richard D. Smith, Pacific Northwest National Laboratory Quantitative and Ultra-Sensitive High Throughput Proteomics

Keynote Lectures

David H. Russell, Texas A&M University

Molecular Imaging Using MALDI and Ion Mobility-Mass Spectrometry: A New

Paradigm for Proteomics

Richard Beger, Food & Drug Administration Metabolic Profiles of Drug Toxicity and Disease

Featured Symposia and Roundtables

Biomarkers: Initiatives, Perspectives & Approaches || How Do We Set Priorities in Drug Discovery & Development? || Outsourcing Trends: Emerging Business Models & Overseas Partners || High Throughput Analysis & Information Management Strategies || Current Strategies & Preferences for Metabolite Identification || Biomarker Discovery || High Throughput ADME & Pharmaceutical Property Profiling || Tissue Imaging: Localization of Drugs & Metabolites || Biomarker Evaluation || Emerging Technologies & Applications

2005 Program Chair

Bradley L. Ackermann, Eli Lilly and Company

Plenary Lecture

R. Graham Cooks, Purdue University

Enabling Biology Through Analytical Innovation: Tissue Imaging in the Ambient Environment Using DESI Mass Spectrometry

Keynote Lectures

Yining Zhao, Pfizer

Modern Separation Science: Quo Vadis? – The Pursuit of Higher Resolution and Higher Speed Separation in Drug Discovery and Development

John T. Stults, Predicant Biosciences

Discovery and Clinical Validation of Serum Biomarkers for Disease Diagnosis

Distinguished Analytical Scientist Award

Mark J. Cole, Pfizer

Featured Symposia and Roundtables

Biomarkers: Proteomics Strategies || Metabolite Identification: Emerging Strategies to Make Better Use of Time & Resources || Chromatography || Bioanalytical: Current Strategies || Pharmaceutical Properties: Compound Library Analysis & Profiling || Biomarkers: Metabonomics Strategies || Bioanalytical: Driving Technologies & Methodologies || Pharmaceutical Properties: HT ADME || Biomarkers: New Technologies & Approaches || NMR Analysis: Emerging Analysis Strategies & Methodologies || Bioanalytical: Exploratory Technologies



Jing-Tao Wu, Millennium Pharmaceuticals

Plenary Lecture

Mark L. Powell, Bristol-Myers Squibb Analytical Chemistry: A Changing Paradigm of Advanced Process Models, Tools and Technologies in R&D

Keynote Lectures

Richard C. King, Merck Research Laboratories

Ion Formation from Complex Solutions: Understanding Matrix Effects and
Ionization Suppression

David M. Lubman, University of Michigan

Markers of Cancer Using a Liquid Proteomics Approach

Distinguished Analytical Scientist Award

Richard C. King, Merck Research Laboratories

Featured Symposia and Roundtables

Proteins and Early Biology || Discovery Strategy: The Minimalist Approach Versus the Fail Faster Model || Predictive Toxicology || Measurement of Drug in Clinical Development || Pharmaceutical Sciences - Analytical New Strategies || Chemistry in Drug Discovery || The Unsolved Mystery: Reactive Metabolites || AAPS/FDA Bioanalytical Workshop: Take Home Messages and Implementation || Clinical Development – Measurement of Drug Effects || Biomarkers in Drug Discovery || Pharmaceutical Sciences - Analytical New Technologies || Emerging New Technologies || Pharmacokinetics & Pharmacodynamics

2007 Program Chair

Nalini Sadagopan, Pfizer

Plenary Lecture

Jonathan L. Josephs, Bristol-Myers Squibb

Why Can't We All Just Get Along: An Integrated Approach to Solving ADME
Issues

Keynote Lectures

Bradley L. Ackermann, Eli Lilly and Company

From Bioanalytical to Biomarkers - Using Quantitative Mass Spectrometry to Address Biological Bottlenecks

Liang Li, University of Alberta

Development and Applications of Improved Sample Handling and LC-MS Techniques for Comprehensive Proteome and Metabolome Analysis

Distinguished Analytical Scientist Award

Bradley L. Ackermann, Eli Lilly and Company

Featured Symposia and Roundtables

Biomarkers in Preclinical Development || Bioanalytical CRO – Assay Transfers || Proteo-Metabonomic Strategies in Drug Development || High Throughput Approaches – Fast Separations || Biologics || Metabolomics and Metabonomics || Omics Technologies || New Technologies and Trends in Bioanalysis || Drug Metabolism in Preclinical and Clinical Development || Driving Pharmaceutical Quality || Biomarkers in Clinical Development || ADME Strategies: Past, Present and Future



Lucinda Cohen, Merck Research Laboratories

Plenary Lecture

David M. Hercules, Vanderbilt University

Mass Spectrometry of Synthetic Polymers: Some Challenges and Some
Successes

Keynote Lectures

Thomas R. Covey, MDS Analytical Technologies Where Can We Go From Here? An Assessment of the Limits to Sensitivity of Electrospray and MALDI

J. Michael Ramsey, University of North Carolina

Protein and Peptide Analysis Using Microfabricated Fluidic Devices

Distinguished Analytical Scientist Award

Thomas R. Covey, MDS Analytical Technologies

Featured Symposia and Roundtables

Excellence in Bioanalysis Through Automation || Insourcing, Outsourcing and Offshoring || Emerging Analytical Tools for Biologics || "Nano" Applications to Small Molecule Analysis || Biomarkers in Preclinical and Clinical Development || Adding Another Dimension to the Quantitation of Peptides and Proteins || Leveraging Analytical Chemistry for Drug Metabolism Studies || Operational Excellence through IT and Hardware Solutions || Approaches to Overcome Poor Pharmacokinetic Properties for Lead Compounds || Is There Life Beyond LC/MS?

2009 Program Chair

Kevin P. Bateman, Merck Frosst Canada

Plenary Lecture

lan Jardine, Thermo Fisher Scientific
The Impact of High-Performance Mass Spectrometry on Biology Research

Keynote Lectures

Walter A. Korfmacher, Schering-Plough Research Institute
Using Mass Spectrometry in Drug Discovery: Past, Present and Future

Thomas A. Baillie, University of Washington
The Impact of Mass Spectrometry in Pharmaceutical Lead Optimization –
Studies on Metabolic Activation

Distinguished Analytical Scientist Award

Walter A. Korfmacher, Schering-Plough Research Institute

Featured Symposia and Roundtables

High Performance Workflows: Emerging Applications for Simultaneous Qualitative-Quantitative Analysis || Why Biomarkers for Toxicology and Clinical Diagnostics Fail or Don't Have Broader Acceptance? || Small Interfering RNA and Gene Silencing: Emerging Opportunities for Analysis in Drug Discovery and the Potential of a Bioanalytical Equivalent || Small Molecule Biomarker Assay Development and Validation || Protein Based Biomarkers || Tools for Understanding Biology Through Analysis || Toxicity Markers || Peptide and Protein Quantitation: Are Trypsin and MRM Sufficient? || High Throughput Quantitation: Going Faster by Going Faster and Going Slower || Maintaining Our Innovative Fitness During Times of Transition



Petia Shipkova, Bristol-Myers Squibb

Plenary Lecture

Bradley L. Ackermann, Eli Lilly and Company
Using Quantitative Mass Spectrometry to Enable Clinical Translation
Through Analysis of Biochemical Markers

Keynote Lectures

Jonathan Josephs, Bristol-Myers Squibb Accuracy for the Masses: Resolution of the Quan/Qual Debate

Mark Sanders, Thermo Fisher Scientific

Resolution for the Masses: The Debate is Over – Now What?

Distinguished Analytical Scientist Award

Mark Sanders, Thermo Fisher Scientific

Featured Symposia and Roundtables

Biomarker/Toxicity Marker Discovery || A Practical Guide to Regulated Bioanalysis || High-Resolution Technologies and Applications || DMPK with Accurate Mass Measurements || Can Dried Blood Spots Revolutionize Our Industry? Case Studies and Practical Considerations || Biologics as Pharmaceutical Agents || Imaging and Tissue Analysis || International Harmonization of Bioanalytical Guidance || Recent Trends in ADME || Protein/Peptide Biomarkers || Bioinformatics || Where Do We Go From Here?

2011 Program Chair

Roger Hayes, Cetero Research

Plenary Lecture

Robert C. Murphy, University of Colorado, Denver Secrets in Lipid Biochemistry Revealed by Mass Spectrometry

Keynote Lectures

lan Blair, University of Pennsylvania Liquid Chromatography-Mass Spectrometry in Pharmacology Research and its Transition to Clinical Applications

Jack Henion, Advion BioSciences & Cornell University
A Scientific Adventure – LC/MS: From Academia to Entrepreneurship

Distinguished Analytical Scientist Award

Jack Henion, Advion BioSciences & Cornell University

Featured Symposia and Roundtables

Biomarkers || The Science of Compliance || Metabolite Identification || Innovation in Regulated Bioanalysis: Fact or Fantasy? || Fast-to-Fail Paradigm || Microfluidics || Globalization of Bioanalytical || Does LC/MS/MS Assay Have a Place in Biologics Development? || CRO-Innovator Interface || New Technologies || Coupled Workflows Enabled by HRMS: Integrated Data Sets to Facilitate Program Progression || Clinical Diagnostics: From Biology to Analytical Chemistry



Joanna Pols, Merck

Plenary Lecture

Lisa A. Shipley, Merck

Navigating the Waters from Scientist to Administrator in an Ever-Changing Environment: A 25 year Journey in the Pharmaceutical Industry

Keynote Lectures

Fred W. McLafferty, Cornell University

Mass Spectrometry: Convenient Characterization of Complex Compunds with Colossal Content of Cool Comprehension

Neil L. Kelleher, Northwestern University Weigh Every Protein

Nathan A. Yates, University of Pittsburgh
How to Keep Your Mass Spectrometer Alive: A Manual of Step-by-Step
Procedures for the Complete Idiot

Distinguished Analytical Scientist Award

Nathan A. Yates, University of Pittsburgh

Featured Symposia and Roundtables

Small Molecule Biomarkers || Regulatory Compliance || Trends in Metabolite Profiling and Identification || Transporters || Food Quality and Safety || Dried Blood Spot Summit || Clinical Diagnostics || Bridging the Gap Between Pharmacokinetics and Pharmacodynamics Through Quantitative LC-MS || Innovation in Regulated Bioanalysis: Yes it is Happening! || Innovator Series Session || Outsourcing: Science, Interaction and Collaboration || Protein Quantitation || High Resolution Quan/Qual || Alternative Instrumentation

2013 Program Chair

Shane Needham, Alturas Analytics

Distinguished Lecture

Richard Kibbey, Yale University

Mitochondrial GTP Cycle: A Novel Metabolic Pathway Regulating Glucose Homeostasis

Plenary Lecture

Ola Saad, Genentech

Bioanalytical Strategy Used for Ado-Trastuzumab Emtansine (T-DM1)

Ellie Guardino, Genentech

Clinical Development of T-DM1

Keynote Lectures

Nathan Yates, University of Pittsburgh

How Cloud Computing Can Extend the Power and Versatility of Mass Spectrometry from the Bench to the Bedside

Fred McLafferty, Cornell University

An Analytical Scientist's Comments On A Distinguished One

Gary Valaskovic, New Objective

From Inspiration to Belief, A Journey of Self-Discovery: Thinking Small, Ultra-Low Flow and Ultra-High Throughput Mass Spectrometry

Distinguished Analytical Scientist Award

Gary A. Valaskovic, New Objective



Featured Symposia and Roundtables

Cancer Metabolism || Rapid Turn-Around-Time of Bioanalytical Data: No One Pays Much Attention Unless There Is A Problem || Fit For Purpose in the Clinical Laboratory || Bioanalytical Laboratory Management || Food Quality & Safety Summit || Microsampling Summit || Mass Spectrometry in the Operating Room: The Urgency of Information and the Requirements of Diagnostics || Shared Workflows: From a Discovery Laboratory to Hospitals || Regulations and Emerging Technology in the Clinical Sciences: The Impact on Research, Patients and Physicians || Innovator Awards || Graduate Student Session || Biomarker and Protein Validations in a Regulated Environment: Emerging Workflows and Approaches || Tools for Data Sharing and Integration || Mass Spectrometry in the Operating Theatre: A Surgeon's Perspective || New Alternative Instrumentation

2014 Program Chairs

Paul Corcoran, McKinley Scientific Gary Valaskovic, New Objective

Distinguished Lecture

Steven Wong, Wake Forest University
Translational Mass Spectrometry Enabling Personalized Medicine

Plenary Lecture

Ann Weber, Merck Adventures in Drug Discovery: Development of JANUVIA for Type 2 Diabetes

Keynote Lectures

Andy Hoofnagle, University of Washington Helping the Clinical Lab Help Patients

Kevin Bateman, Merck Bioanalysis, Smart PK/PD and the Future of Drug Development

Distinguished Analytical Scientist Award

Kevin Bateman, Merck

Featured Symposia and Roundtables

Current and Future Needs of Mass Spectrometry in Clinical Sciences || Crystal City V Guidance: How Is the Guidance Being Used? || Biomarkers and Diagnostics for Rare Diseases || Novel Solutions to Novel Milla & Macro-Molecule Analysis by LC/MS || Food Quality & Safety Summit || Microsampling Summit || Challenges/Innovation and New Technologies in the Modern Bioanalysis Lab || Metabolomics: The Art and Lab Science of Expressionist Genetics || Innovator Awards || Defining the Future of Clinical Protein Biomarker Discovery, Development and Deployment || Steven A. Hofstadler Graduate Student Session || Bioanalysis in Personalized Medicine: Where Do Biomarkers Fit In? || Measurement and Application of Metabolite Biomarkers || The Ever Expanding Role for the Definitive Structure Elucidation of Drug Metabolites, Degredates, and Trace Impurities in the Pharmaceutical Industry || New Alternative Insturmentation